Data from a preclinical study assessing Mission Therapeutics Ltd.’s clinical-stage USP30 inhibitor MTX-652, for the prevention of transverse aortic constriction (TAC)-induced cardiac hypertrophy and remodeling, were recently presented.
Seismic Therapeutic Inc. has provided preclinical data for S-4321, a novel dual-cell bidirectional (DcB) PD-1:FcγRIIb antibody being developed for the treatment of autoimmune disease.
Kinnate Biopharma Inc. and affiliated organizations recently reported preclinical data for the novel brain-penetrant combination therapy using the MEK inhibitor KIN-7136 and the RAF inhibitor KIN-8391, as a novel therapeutic strategy for the treatment of melanoma brain metastasis.
Researchers from Memorial Sloan Kettering Cancer Center and affiliated organizations revealed findings from the preclinical evaluation of 1H5, a novel monoclonal antibody (mAb) candidate that inhibits the NOTCH signaling pathway and is being developed for the treatment of high-grade gliomas (HGGs).
There is increasing interest in developing precision immunotherapies that target tumors but with minimal impact on healthy tissues. IL-12 is a potent immunostimulatory cytokine that has shown effective antitumoral activity in the preclinical setting, but its systemic delivery may be accompanied by off-target effects.
Researchers from presented preclinical data for AVX-70371, a novel therapeutic vaccine being developed for the treatment of chronic hepatitis B virus (HBV) infection.